Week in Review: Suzhou Connect Biopharma In-Licenses Anti-Inflammatories From Arena Pharmaceuticals, Inc.

Published: Jul 30, 2012

by Richard Daverman, PhD

July 28, 2012 -- Suzhou Connect Biopharma, a new startup, in-licensed two series of anti-inflammatory compounds from Arena Pharma of San Diego; Transgene of France and China’s Tasly Pharma announced their JV will develop four of Transgene’s biotech immunotherapeutic candidates for China; SUMEC landed the exclusive right to distribute Aurora Imaging Technology’s breast imaging machines in China; Fenwal Holdings, a US company with a China JV, was bought by German medical equipment maker Fresenius for $1.1 billion; and chronic disease – diabetes, heart disease cancer – is placing a heavy burden on China’s healthcare system. More details….

Stock Symbols: (NSDQ: ARNA) (Euronext: TNG) (SHA: 600535) (FEX: FME)

Back to news